Aged 49, joined our Group as CEO on August 1, 2018. He has been our executive director since November 23, 2018. Mr. Liu is responsible for overall strategic planning, business direction and daily management of the Company. Mr. Liu has over 20 years of experience in the pharmaceutical industry. Prior to joining our Group, he served as the chairman and general manager in Santen Pharmaceutical (China) Co., Ltd. (参天制药（中国）有限公司) from October 2014 to July 2018. From February 2009 to September 2014, Mr. Liu served as the head of pharmaceutical affair division and later became the general manager of Eisai (China) Inc. (卫材（中国）药业有限公司), responsible for the management of pharmaceutical affairs and development, and the overall corporate operation, respectively. Mr. Liu has been serving as a director of EyePoint Pharmaceuticals Inc. (Nasdaq: EYPT) since January 2021.

Mr. Liu obtained his Master of Science in pharmacology from Dalhousie University in Canada in August 2003. He graduated with a Bachelor of Science in pharmaceutical chemistry from Shanghai Medical University (上海医科大学), in Shanghai, China in July 1993.

Aged 48, joined our Group in September 3, 2018 as the vice president of registration affairs. He has been our executive director since April 24, 2020, and our chief development officer since June 1, 2020. Dr. Hu is primarily responsible for participating in strategic planning and management of CMC and registration affairs. Dr. Hu has around 20 years of experience in pharmaceutical industry. From July 2006 to August 2018, he held positions including plant technique and registration group manager, registration and pharmaceutical department director, clinical development department director and internal audit department director in Santen Pharmaceutical (China) Co., Ltd., mainly responsible for clinical development compliance and other drug-related regulations and compliance.

Mr. Liu obtained his Master of Science in pharmacology from Dalhousie University in Canada in August 2003. He graduated with a Bachelor of Science in pharmaceutical chemistry from Shanghai Medical University (上海医科大学), in Shanghai, China in July 1993.

Aged 40, he has been the Vice President of Clinical Research and Development since 16 May 2023 and is responsible for leading clinical development. He joined the Group on 1 April 2019 as the Director of Clinical Medicine. He has been the Vice President of Registration Affairs since 1 October 2022. Prior to joining the Group, Dr. Shen served as the manager of the medical information department of Santen Pharmaceutical (China) Co., Ltd. from September 2015 to March 2019. From August 2013 to September 2015, he served as the medical information manager in Shanghai Roche Pharmaceutical Co., Ltd. From July 2010 to July 2012, he served as a postdoctoral fellow at the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.

Dr. Shen obtained his doctorate degree in pharmacology from China Pharmaceutical University in June 2010. He graduated from College of Medicine of Zhengzhou University in June 2005 with a bachelor's degree in pharmacy.

Aged 37, has been our chief commercial officer since January 1, 2021, responsible for product commercialization. Mr. Zuo served as our vice president of commercialization from September 2018 to January 2021. Prior to joining our Group, Mr. Zuo held positions including manager of business development department, director of business development department and head of sales of the pharmaceutical department of Santen Pharmaceutical (China) Co., Ltd. from April 2015 to August 2018. From October 2010 to March 2015, he successively served as associate product manager and district sales manager of gastrointestinal and liver diseases department in Eisai (China) Inc., where he was responsible for sales of drugs. From June 2009 to September 2010, he served as a preclinical project manager of R&D department in Shanghai Hengrui Pharmaceutical Co., Ltd. (上海恒瑞医药有限公司).

Mr. Zuo obtained his master’s degree in pharmacology in Shanghai Institute of Pharmaceutical Industry (上海医药工业研究院) in May 2009. He graduated with bachelor’s degree in pharmacy from Yantai University (烟台大学) in June 2006.

Mr. Tim Ruan will be responsible for the execution and management of the Group's financial affairs and investor relations management, and has over 10 years of extensive experience in global capital markets, mergers and acquisitions, and financial management.

Prior to joining the Group, Mr. Ruan served as an executive director in investment banking division of Goldman Sachs since 2020. Prior to that, he held the positions of vice president and manager at Morgan Stanley and Nomura Securities respectively. He was also an associate in the capital markets and mergers and acquisitions department of Sullivan & Cromwell, a US law firm. Mr. Ruan holds a master’s degree of science (biotechnology) from The Hong Kong University of Science and Technology and a bachelor’s degree of commerce and a bachelor’s degree of laws from The University of New South Wales, Australia.